588720-36-9

Basic information

• Product Name: 3-Pyridinecarboxylic acid, 6-[[(methylsulfonyl)oxy]methyl]-, methyl ester
• CAS NO: 588720-36-9
• Molecular Formula: C9H11NO5S
• Molecular Weight: 245.256
• Mol File: 588720-36-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-Pyridinecarboxylic acid, 6-[[(methylsulfonyl)oxy]methyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylic acid, 6-[[(methylsulfonyl)oxy]methyl]-, methyl ester(588720-36-9)
• EPA Substance Registry System: 3-Pyridinecarboxylic acid, 6-[[(methylsulfonyl)oxy]methyl]-, methyl ester(588720-36-9)

Safety Data

• Hazardous Substances Data: 588720-36-9(Hazardous Substances Data)

Upstream product

• 56026-36-9 methyl 6-(hydroxymethyl)nicotinate 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 914669-95-7 4-(6-((dimethylamino)methyl)pyridin-3-yl)-N-(4-(pentyloxy)-3-(trifluoromethyl)phenyl)thiazol-2-amine 

Relevant articles and documents

Phosphodiesterase inhibitor, and applications thereof

The invention belongs to the technical field of medicine, and more specifically relates to a phosphodiesterase 9 (PDE9) inhibitor represented by formula I, and pharmaceutically acceptable salts, solvates, polymorphic substances, and isomers thereof, and also relates to medicinal preparations, and pharmaceutical compositions of the above compounds, and applications of the medicinal preparations andpharmaceutical compositions. The compounds and the pharmaceutically acceptable salts, solvates, polymorphic substances, and isomers can be used in treatment of phosphodiesterase 9 (PDE9) abnormal expression mediated related diseases.

NOVEL CHROMANE COMPOUND FOR THE TREATMENT OF PAIN DISORDERS

The present invention relates to the compound N-[(3S)-5-(5-methoxypyrazin-2-yl)-3,4- dihydro-2H-chromen-3-yl]-6-[(2,2,2-trifluoroethoxy)methyl]pyridine-3-carboxamide, or a pharmaceutical composition comprising said compound and to the use of said compounds in therapy.

HETEROARYL SUBSTITUTED THIAZOLES

The invention provides heteroaryl substituted thiazolo compounds of Formula I and II and pharmaceutically acceptable salts thereof. The variables A and R3 to R7 are defined herein. The invention also includes methods for preparing compounds and salts of Formula I and II. The present invention also includes pharmaceutical compositions containing heteroaryl substituted thiazolo compounds and methods for using heteroaryl substituted thiazolo compounds, including methods for using the compounds in the treatment of hepatitis C virus.